Immune checkpoint inhibitor (ICI), such as those targeting programmed death 1 (PD1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA4), have both demonstrated remarkable anti-tumor effects in patients with advanced melanoma, renal cell carcinoma, non-small cell lung cancer, and malignant pleural mesothelioma [9]. This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.